Impel NeuroPharma press release (IMPL): Q4 Non-GAAP EPS of -$0.97 beats by $0.06.Revenue of $5.01M (+735.0% Y/Y) misses by $0.24M.As of December 31, 2022, Impel had approximately...
Burlingame, Jan. 09, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights analysis, the U.S. nasal spray market is estimated to be valued at...